GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Femtobiomed Inc (XKRX:327610) » Definitions » Research & Development

Femtobiomed (XKRX:327610) Research & Development : ₩1,503.4 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Femtobiomed Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Femtobiomed's Research & Development for the six months ended in Dec. 2024 was ₩1,503.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was ₩1,503.4 Mil.


Femtobiomed Research & Development Historical Data

The historical data trend for Femtobiomed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femtobiomed Research & Development Chart

Femtobiomed Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 1,248.74 1,718.55 2,814.24 842.46 1,503.40

Femtobiomed Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development Get a 7-Day Free Trial 1,248.74 1,718.55 2,814.24 842.46 1,503.40

Femtobiomed Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was ₩1,503.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Femtobiomed  (XKRX:327610) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Femtobiomed Research & Development Related Terms

Thank you for viewing the detailed overview of Femtobiomed's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Femtobiomed Business Description

Traded in Other Exchanges
N/A
Address
17 Pangyo-ro 228 (ibaegisippal) beo, Sampyeong-dong, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13487
Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.

Femtobiomed Headlines

No Headlines